Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013).

Released online June 26, 2014 Mailing address: Scientific Committee of the Japanese Circulation Society, 18F Imperial Hotel Tower, 1-1-1 Uchisaiwai-cho, Chiyoda-ku, Tokyo 100-0011, Japan. E-mail: meeting@j-circ.or.jp This English language document is a revised digest version of Guidelines for Pharmacotherapy of Atrial Fibrillation reported at the Japanese Circulation Society Joint Working Groups performed in 2012 (Website: http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_d.pdf). Joint Working Groups: The Japanese Circulation Society, The Japanese College of Cardiology, The Japanese Society of Electrocardiology, The Japanese Heart Rhythm Society ISSN-1346-9843 doi: 10.1253/circj.CJ-66-0092 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013) – Digest Version –

[1]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[2]  M. Hochman.  Rate Control versus Rhythm Control for Atrial Fibrillation , 2013 .

[3]  S. Connolly,et al.  Dabigatran versus warfarin in patients with mechanical heart valves. , 2013, The New England journal of medicine.

[4]  H. Inoue,et al.  Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study. , 2013, Journal of cardiology.

[5]  R. Charnigo,et al.  Increased mortality among patients taking digoxin--analysis from the AFFIRM study. , 2013, European heart journal.

[6]  W. Shimizu,et al.  Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[7]  K. Furie,et al.  Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. , 2012, Stroke.

[8]  S. Hohnloser,et al.  Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial , 2012, The Lancet.

[9]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[11]  D. Roden,et al.  Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[12]  H. Daida,et al.  Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial , 2012, Heart.

[13]  M. Hori,et al.  Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[14]  K. Lunetta,et al.  Meta-analysis identifies six new susceptibility loci for atrial fibrillation , 2012, Nature Genetics.

[15]  S. Yusuf,et al.  Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial , 2012, Stroke.

[16]  Stanley Nattel,et al.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.

[17]  M. Peláez-Luna,et al.  Percutaneous endoscopic gastrostomy complication rates and compliance with the American Society for Gastrointestinal Endoscopy guidelines for the management of antithrombotic therapy. , 2012, JPEN. Journal of parenteral and enteral nutrition.

[18]  G. Lip,et al.  Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. , 2012, Chest.

[19]  Salim Yusuf,et al.  Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial , 2011, Annals of Internal Medicine.

[20]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[21]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[22]  T. Uejima,et al.  Recent mortality of Japanese patients with atrial fibrillation in an urban city of Tokyo. , 2011, Journal of cardiology.

[23]  A. Folsom,et al.  Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. , 2011, Heart Rhythm.

[24]  S. Yusuf,et al.  Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.

[25]  K. Okumura,et al.  Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[26]  M. Hirai,et al.  Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[27]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[28]  M. Pfeffer,et al.  Irbesartan in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[29]  J. Tolstrup,et al.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.

[30]  W. Elliott.  Risk for Incident Atrial Fibrillation in Patients Who Receive Antihypertensive Drugs: A Nested Case–Control Study , 2011 .

[31]  M. Shoda,et al.  Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[32]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[33]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[34]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[35]  S. Connolly,et al.  Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). , 2010, Heart rhythm.

[36]  K. Nagata,et al.  Blood Pressure Levels and Bleeding Events During Antithrombotic Therapy: The Bleeding With Antithrombotic Therapy (BAT) Study , 2010, Stroke.

[37]  Otto Kamp,et al.  Lenient versus strict rate control in patients with atrial fibrillation. , 2010, The New England journal of medicine.

[38]  K. Chien,et al.  Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. , 2010, International journal of cardiology.

[39]  Robby Nieuwlaat,et al.  Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. , 2010, Journal of the American College of Cardiology.

[40]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[41]  Elia Biganzoli,et al.  Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.

[42]  I. Savelieva,et al.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[43]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[44]  M. Horie,et al.  Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. , 2009, International journal of cardiology.

[45]  T. Tanabe,et al.  Dose-Response Effects of Bepridil in Patients With Persistent Atrial Fibrillation Monitored With Transtelephonic Electrocardiograms , 2009 .

[46]  T. Lumley,et al.  Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. , 2009, American journal of hypertension.

[47]  A. Maggioni,et al.  Valsartan for prevention of recurrent atrial fibrillation. , 2009, The New England journal of medicine.

[48]  M. Hirai,et al.  Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[49]  Wi-Sun Ryu,et al.  Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage , 2009, Neurology.

[50]  M. Rosenqvist,et al.  Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. , 2008, European heart journal.

[51]  D. Roden,et al.  Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. , 2009, American heart journal.

[52]  M. de Andrade,et al.  Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. , 2008, The New England journal of medicine.

[53]  K. Nagata,et al.  Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease: A Prospective, Multicenter, Observational Study , 2008, Stroke.

[54]  D. Roden,et al.  Metabolic Syndrome and Risk of Development of Atrial Fibrillation: The Niigata Preventive Medicine Study , 2008, Circulation.

[55]  A. Raviele,et al.  Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation A Meta-Analysis of Randomized Controlled Trials. , 2008, Journal of atrial fibrillation.

[56]  Salim Yusuf,et al.  Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. , 2007, Journal of the American College of Cardiology.

[57]  K. Kumagai,et al.  Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[58]  Eric E. Smith,et al.  Variants conferring risk of atrial fibrillation on chromosome 4q25 , 2007, Nature.

[59]  L. Frost.  Lone atrial fibrillation: good, bad, or ugly? , 2007, Circulation.

[60]  T. Olson,et al.  A Common Polymorphism in SCN5A is Associated with Lone Atrial Fibrillation , 2007, Clinical pharmacology and therapeutics.

[61]  David O. Martin,et al.  Pulmonary vein total occlusion following catheter ablation for atrial fibrillation: clinical implications after long-term follow-up. , 2006, Journal of the American College of Cardiology.

[62]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study , 2006, Circulation.

[63]  Pill-in-the-pocket approach for paroxysmal atrial fibrillation by cibenzoline succinate , 2006 .

[64]  C. Negrão,et al.  Selective Atrial Vagal Denervation Guided by Evoked Vagal Reflex to Treat Patients With Paroxysmal Atrial Fibrillation , 2006, Circulation.

[65]  F. Morady,et al.  Risk of Thromboembolic Events After Percutaneous Left Atrial Radiofrequency Ablation of Atrial Fibrillation , 2006, Circulation.

[66]  Douglas L. Jones,et al.  Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. , 2006, The New England journal of medicine.

[67]  Prashanthan Sanders,et al.  Phrenic nerve injury after atrial fibrillation catheter ablation: characterization and outcome in a multicenter study. , 2006, Journal of the American College of Cardiology.

[68]  A. Iwasa,et al.  D-dimer level influences thromboembolic events in patients with atrial fibrillation. , 2006, International journal of cardiology.

[69]  W. Saliba,et al.  Brief Communication: AtrialEsophageal Fistulas after Radiofrequency Ablation , 2006, Annals of Internal Medicine.

[70]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[71]  Frank Bogun,et al.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation. , 2006, The New England journal of medicine.

[72]  Kiyoshi Yoshida,et al.  Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. , 2006, Stroke.

[73]  A. Waldo.  Angiotensin II Receptor Blockade Reduces New-Onset Atrial Fibrillation and Subsequent Stroke Compared to Atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study , 2006 .

[74]  M. Pfeffer,et al.  Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, American heart journal.

[75]  Nobuyuki Yasui,et al.  [Intracerebral hemorrhage]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[76]  Prashanthan Sanders,et al.  Techniques, Evaluation, and Consequences of Linear Block at the Left Atrial Roof in Paroxysmal Atrial Fibrillation: A Prospective Randomized Study , 2005, Circulation.

[77]  F. Morady,et al.  Randomized comparison of encircling and nonencircling left atrial ablation for chronic atrial fibrillation. , 2005, Heart rhythm.

[78]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[79]  H. Ueshima,et al.  Rapid Increase in Estimated Number of Persons with Atrial Fibrillation in Japan: An Analysis from National Surveys on Cardiovascular Diseases in 1980, 1990 and 2000 , 2005, Journal of epidemiology.

[80]  R. Hart,et al.  Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas , 2005, Stroke.

[81]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[82]  Douglas Packer,et al.  Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation.

[83]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005, American heart journal.

[84]  J. Jeong.  Prevalence of and Risk Factors for Atrial Fibrillation in Korean Adults Older than 40 Years , 2005, Journal of Korean medical science.

[85]  P. Alboni,et al.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. , 2004, The New England journal of medicine.

[86]  Sabine Ernst,et al.  Complete Isolation of Left Atrium Surrounding the Pulmonary Veins: New Insights From the Double-Lasso Technique in Paroxysmal Atrial Fibrillation , 2004, Circulation.

[87]  S. Kjeldsen,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆ , 2004 .

[88]  Ralph B D'Agostino,et al.  Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. , 2004, JAMA.

[89]  K. Nademanee,et al.  A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. , 2004, Journal of the American College of Cardiology.

[90]  T. Yamashita,et al.  Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[91]  K. Saku,et al.  The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. , 2003, Cardiovascular research.

[92]  S. Umemura,et al.  [Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: a case report]. , 2003, Journal of cardiology.

[93]  D. Beevers,et al.  More evidence on blocking the renin–angiotensin–aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2) , 2003, Journal of Human Hypertension.

[94]  W. Maisel.  Autonomic modulation preceding the onset of atrial fibrillation. , 2003, Journal of the American College of Cardiology.

[95]  J. Katz,et al.  Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. , 2003, Ophthalmology.

[96]  Tadashi Yamamoto,et al.  Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. , 2003, Biochemical and biophysical research communications.

[97]  Douglas L Packer,et al.  Familial atrial fibrillation is a genetically heterogeneous disorder. , 2003, Journal of the American College of Cardiology.

[98]  K. Arakawa,et al.  Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. , 2003, Journal of the American College of Cardiology.

[99]  A. Ducharme,et al.  Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials , 2003, Circulation.

[100]  U. Tebbe,et al.  Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. , 2003, Journal of the American College of Cardiology.

[101]  Sander Verheule,et al.  Arrhythmogenic Substrate of the Pulmonary Veins Assessed by High-Resolution Optical Mapping , 2003, Circulation.

[102]  Wei Huang,et al.  KCNQ1 Gain-of-Function Mutation in Familial Atrial Fibrillation , 2003, Science.

[103]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[104]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[105]  H. Snooks,et al.  Can warfarin be continued during dental extraction? Results of a randomized controlled trial. , 2002, The British journal of oral & maxillofacial surgery.

[106]  M. Allessie,et al.  Electrical, contractile and structural remodeling during atrial fibrillation. , 2002, Cardiovascular research.

[107]  Hakan Oral,et al.  Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation , 2002, Circulation.

[108]  Y C Chen,et al.  Effects of Rapid Atrial Pacing on the Arrhythmogenic Activity of Single Cardiomyocytes From Pulmonary Veins: Implication in Initiation of Atrial Fibrillation , 2001, Circulation.

[109]  K. Minematsu,et al.  Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. , 2001, Internal medicine.

[110]  S. Nattel,et al.  Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure , 2001, Circulation.

[111]  A Majeed,et al.  Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database , 2001, Heart.

[112]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[113]  David Newman,et al.  New-Onset Atrial Fibrillation: Sex Differences in Presentation, Treatment, and Outcome , 2001, Circulation.

[114]  J. Halperin,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[115]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[116]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): a randomised trial , 2001 .

[117]  Gabriele Vicedomini,et al.  Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia A New Anatomic Approach for Curing Atrial Fibrillation , 2000 .

[118]  S. Nattel,et al.  Ionic Remodeling in the Heart: Pathophysiological Significance and New Therapeutic Opportunities for Atrial Fibrillation , 2000, Circulation research.

[119]  C. Good,et al.  Amiodarone to prevent recurrence of atrial fibrillation. , 2000, The New England journal of medicine.

[120]  K. Stangl,et al.  Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. , 2000, Journal of the American College of Cardiology.

[121]  G. Naccarelli,et al.  Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. , 2000, The American journal of cardiology.

[122]  M. Inoue,et al.  Short-term effects of rapid pacing on mRNA level of voltage-dependent K(+) channels in rat atrium: electrical remodeling in paroxysmal atrial tachycardia. , 2000, Circulation.

[123]  N. Ishikawa,et al.  Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. , 2000, European heart journal.

[124]  R. Hart,et al.  Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention , 1999, Annals of Internal Medicine.

[125]  C. Tai,et al.  Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. , 1999, Circulation.

[126]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[127]  B. Gersh,et al.  Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. , 1999, Archives of internal medicine.

[128]  J Clémenty,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[129]  A. Camm,et al.  Classification of Atrial Fibrillation , 1997, The American journal of cardiology.

[130]  Transesophageal Echocardiographic Correlates of Thromboembolism in High-Risk Patients with Nonvalvular Atrial Fibrillation , 1998, Annals of Internal Medicine.

[131]  Haruko Yamamoto,et al.  Predisposing factors to enlargement of spontaneous intracerebral hematoma. , 1997, Stroke.

[132]  H. Okayama,et al.  Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. , 1997, Circulation.

[133]  J Clémenty,et al.  A focal source of atrial fibrillation treated by discrete radiofrequency ablation. , 1997, Circulation.

[134]  A L Waldo,et al.  Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance. , 1997, Circulation.

[135]  H. Crijns,et al.  Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. , 1996, Archives of internal medicine.

[136]  H. Hayakawa,et al.  Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators. , 1996, The American journal of cardiology.

[137]  J. Soler‐Soler,et al.  Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. , 1996, Journal of the American College of Cardiology.

[138]  V. Fuster,et al.  Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. , 1996, Circulation.

[139]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[140]  K. Ieki,et al.  Prediction of early development of chronic nonrheumatic atrial fibrillation. , 1995, Japanese heart journal.

[141]  G. Lip.  The coagulation system is activated in idiopathic cardiomyopathy. , 1995, Journal of the American College of Cardiology.

[142]  A. Capucci,et al.  Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. , 1994 .

[143]  J. Gardin,et al.  Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). , 1994, The American journal of cardiology.

[144]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[145]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[146]  W. Baxter,et al.  Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. , 1993, Circulation research.

[147]  R. Falk.  Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter , 1992, Annals of Internal Medicine.

[148]  A. Capucci,et al.  Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. , 1992, The American journal of cardiology.

[149]  F. Loop,et al.  Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. , 1992, Journal of the American College of Cardiology.

[150]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[151]  J. Rawles,et al.  What is meant by a "controlled" ventricular rate in atrial fibrillation? , 1990, British heart journal.

[152]  M. Allessie,et al.  Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarcts. , 1988, Circulation research.

[153]  M. Allessie,et al.  Length of Excitation Wave and Susceptibility to Reentrant Atrial Arrhythmias in Normal Conscious Dogs , 1988, Circulation research.

[154]  R. Coleman,et al.  Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. , 1986, The American journal of cardiology.

[155]  M. Allessie,et al.  Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation , 1985 .

[156]  C. Pollick.  Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. , 1982, The New England journal of medicine.

[157]  Allessie,et al.  Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. , 1977, Circulation research.

[158]  M. A. Kaplan,et al.  Ventricular fibrillation in the Wolff-Parkinson-White syndrome. , 1969, The American journal of cardiology.

[159]  W. Evans,et al.  LONE AURICULAR FIBRILLATION , 1954, British heart journal.

[160]  Rimm,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.